Literature DB >> 23653056

Clinical characteristics and effectiveness of lansoprazole in Japanese patients with gastroesophageal reflux disease and dyspepsia.

Yoshikazu Kinoshita1, Hiroto Miwa, Katsuyuki Sanada, Koji Miyata, Ken Haruma.   

Abstract

BACKGROUND: Patients with gastroesophageal reflux disease (GERD) frequently have symptoms of dyspepsia in addition to reflux symptoms. Treatment options for dyspepsia are not standardized. The aim of this study was to clarify the therapeutic effect of lansoprazole on dyspepsia in Japanese patients with GERD.
METHODS: GERD patients with dyspepsia were enrolled and treated with lansoprazole 15 or 30 mg once daily for 4 weeks. Reflux and dyspeptic symptoms were assessed by questionnaires before treatment, and 2 and 4 weeks after the start of lansoprazole treatment.
RESULTS: In the effectiveness analysis set (n = 12,653), heartburn was reported by 91.6 % of patients at study enrollment. Postprandial fullness was the most frequently reported dyspepsia symptom at the start of the study, reported by 79.0 % of enrolled patients. After 4 weeks of lansoprazole treatment, heartburn symptoms were improved in 75.7 % of patients and symptoms of postprandial fullness were improved in 68.7 % of patients. The therapeutic effect of low and high doses of lansoprazole on dyspepsia, as well as on reflux symptoms, was approximately 10 % higher in patients with endoscopy-confirmed erosive esophagitis (60.1-82.2 %), than in patients with non-erosive reflux diseases (53.0-73.3 %). Lansoprazole was well tolerated.
CONCLUSION: In this large-scale clinical study, lansoprazole effectively relieved dyspepsia in addition to reflux symptoms in patients with GERD.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23653056     DOI: 10.1007/s00535-013-0812-3

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  53 in total

1.  Importance of vertebral fracture and body mass index in the pathogenesis of gastroesophageal reflux disease.

Authors:  Ryuichi Iwakiri; Kazuma Fujimoto
Journal:  Intern Med       Date:  2008-09-16       Impact factor: 1.271

2.  Prevalence of overlaps between GERD, FD and IBS and impact on health-related quality of life.

Authors:  Makiko Kaji; Yasuhiro Fujiwara; Masatsugu Shiba; Yukie Kohata; Hirokazu Yamagami; Tetsuya Tanigawa; Kenji Watanabe; Toshio Watanabe; Kazunari Tominaga; Tetsuo Arakawa
Journal:  J Gastroenterol Hepatol       Date:  2010-06       Impact factor: 4.029

3.  Non-erosive reflux disease (NERD)--acid reflux and symptom patterns.

Authors:  S D Martinez; I B Malagon; H S Garewal; H Cui; R Fass
Journal:  Aliment Pharmacol Ther       Date:  2003-02-15       Impact factor: 8.171

4.  Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs-TORNADO study: a multicenter prospective study by the Acid-Related Symptom Research Group in Japan.

Authors:  Takahisa Furuta; Tomohiko Shimatani; Mitsushige Sugimoto; Shunji Ishihara; Yasuhiro Fujiwara; Motoyasu Kusano; Tomoyuki Koike; Michio Hongo; Tsutomu Chiba; Yoshikazu Kinoshita
Journal:  J Gastroenterol       Date:  2011-08-24       Impact factor: 7.527

5.  Comparison of PPIs and H2-receptor antagonists plus prokinetics for dysmotility-like dyspepsia.

Authors:  Masahiro Sakaguchi; Miyuki Takao; Yasuo Ohyama; Hiroshi Oka; Hiroshi Yamashita; Takumi Fukuchi; Kiyoshi Ashida; Masahiro Murotani; Masuyo Murotani; Kazuo Majima; Hiroshi Morikawa; Takashi Hashimoto; Keisuke Kiyota; Hirohiko Esaki; Kanji Amemoto; Gouhei Isowa; Fumiyuki Takao
Journal:  World J Gastroenterol       Date:  2012-04-07       Impact factor: 5.742

Review 6.  Impaired gastric accommodation and its role in dyspepsia.

Authors:  S Kindt; J Tack
Journal:  Gut       Date:  2006-07-19       Impact factor: 23.059

7.  A randomized trial comparing omeprazole, ranitidine, cisapride, or placebo in helicobacter pylori negative, primary care patients with dyspepsia: the CADET-HN Study.

Authors:  Sander J O Veldhuyzen van Zanten; Naoki Chiba; David Armstrong; Alan Barkun; Alan Thomson; Sandra Smyth; Sergio Escobedo; Joanna Lee; Paul Sinclair
Journal:  Am J Gastroenterol       Date:  2005-07       Impact factor: 10.864

8.  Lansoprazole in the treatment of functional dyspepsia: two double-blind, randomized, placebo-controlled trials.

Authors:  David A Peura; Thomas O G Kovacs; David C Metz; Nancy Siepman; Betsy L Pilmer; Nicholas J Talley
Journal:  Am J Med       Date:  2004-06-01       Impact factor: 4.965

9.  Double-blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux oesophagitis.

Authors:  E C Klinkenberg-Knol; J M Jansen; H P Festen; S G Meuwissen; C B Lamers
Journal:  Lancet       Date:  1987-02-14       Impact factor: 79.321

10.  Clinical symptoms in endoscopic reflux esophagitis: evaluation in 8031 adult subjects.

Authors:  Kazuyo Okamoto; Ryuichi Iwakiri; Mitsuru Mori; Megumi Hara; Kayoko Oda; Akiko Danjo; Akifumi Ootani; Hiroyuki Sakata; Kazuma Fujimoto
Journal:  Dig Dis Sci       Date:  2003-12       Impact factor: 3.199

View more
  5 in total

1.  Reply to the letter by E. Savarino et al. regarding "The placebo effect is a relevant factor in evaluating effectiveness of therapies in functional gastrointestinal disorders".

Authors:  Yoshikazu Kinoshita; Hiroto Miwa; Katsuyuki Sanada; Koji Miyata; Ken Haruma
Journal:  J Gastroenterol       Date:  2014-06-29       Impact factor: 7.527

2.  The placebo effect is a relevant factor in evaluating effectiveness of therapies in functional gastrointestinal disorders.

Authors:  Edoardo Savarino; Chiara De Cassan; Giorgia Bodini; Manuele Furnari; Nicola de Bortoli; Vincenzo Savarino
Journal:  J Gastroenterol       Date:  2014-06-28       Impact factor: 7.527

3.  No increase in gastric acid secretion in healthy Japanese over the past two decades.

Authors:  Norihisa Ishimura; Yasuko Owada; Masahito Aimi; Tadayuki Oshima; Tomoari Kamada; Kazuhiko Inoue; Hironobu Mikami; Toshihisa Takeuchi; Hiroto Miwa; Kazuhide Higuchi; Yoshikazu Kinoshita
Journal:  J Gastroenterol       Date:  2014-12-14       Impact factor: 7.527

4.  Barretts's carcinogenesis.

Authors:  Ken-Ichi Mukaisho; Shunpei Kanai; Ryoji Kushima; Takahisa Nakayama; Takanori Hattori; Hiroyuki Sugihara
Journal:  Pathol Int       Date:  2019-07-10       Impact factor: 2.534

Review 5.  Gastroesophageal reflux disease, functional dyspepsia and irritable bowel syndrome: common overlapping gastrointestinal disorders.

Authors:  Nicola de Bortoli; Salvatore Tolone; Marzio Frazzoni; Irene Martinucci; Giulia Sgherri; Eleonora Albano; Linda Ceccarelli; Cristina Stasi; Massimo Bellini; Vincenzo Savarino; Edoardo V Savarino; Santino Marchi
Journal:  Ann Gastroenterol       Date:  2018-09-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.